Clinical trial registry record

Microneedle Versus Fractional CO₂ Laser for Skin Aging Treatment With Stem Cell Secretome in Indonesian Adult Women

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated February 13, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05508191
Last registry update
February 13, 2023
Status
Completed
Phase
Phase not reported
Sponsor
Shannaz Nadia Yusharyahya
Enrollment
30
Countries
Indonesia
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
30
Population
FEMALE · 35 Years to 59 Years
Duration
2022-08-17 to 2022-12-31
Intervention
Fractional CO₂ Laser; Microneedle
Comparator
Not reported
Outcomes measured
Skin aging changes evaluated by dermoscopy photoaging scale (DPAS) — Week 0 (baseline), week 2 before intervention, wee…; Skin aging changes evaluated by Janus-3Ⓡ skin analyzer — Week 0 (baseline), week 2 before intervention, week 4 before i…; Skin capacitance evaluated by the CorneometerⓇ — Week 0 (baseline), week 2 before intervention, week 4 before intervent…; Transepidermal water loss evaluated by the TewameterⓇ — Week 0 (baseline), week 2 before intervention, week 4 before in…; Likert scale for the satisfaction degree — Week 6 (end of trial); Visual analog scale (VAS) of pain for the convenience degree — Week 6 (end of trial); Number of adverse events experienced during the clinical trial — Week 2 thirty minutes after intervention, week 4 thirt…; Subjective preference to treatment — Week 6 (end of trial)
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Skin ageing · 100%Title contains controlled term: skin aging. Abstract contains controlled term: skin aging. Source terminology contains: skin aging. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.
  • Stem cells · 100%Title contains controlled term: stem cell. Abstract contains controlled term: stem cell. Title supplies longevity context: aging. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.